Annual Operating Expenses
$380.50 M
+$86.92 M+29.61%
December 31, 2023
Summary
- As of February 25, 2025, MDGL annual total operating expenses is $380.50 million, with the most recent change of +$86.92 million (+29.61%) on December 31, 2023.
- During the last 3 years, MDGL annual operating expenses has risen by +$173.82 million (+84.11%).
- MDGL annual operating expenses is now at all-time high.
Performance
MDGL Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$176.33 M
-$212.00 K-0.12%
September 30, 2024
Summary
- As of February 25, 2025, MDGL quarterly total operating expenses is $176.33 million, with the most recent change of -$212.00 thousand (-0.12%) on September 30, 2024.
- Over the past year, MDGL quarterly operating expenses has dropped by -$212.00 thousand (-0.12%).
- MDGL quarterly operating expenses is now -0.12% below its all-time high of $176.54 million, reached on June 30, 2024.
Performance
MDGL Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
MDGL Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +29.6% | -0.1% |
| 3 y3 years | +84.1% | -0.1% |
| 5 y5 years | +835.3% | -0.1% |
MDGL Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +56.9% | -0.1% | +206.2% |
| 5 y | 5-year | at high | +300.6% | -0.1% | +488.7% |
| alltime | all time | at high | >+9999.0% | -0.1% | >+9999.0% |
Madrigal Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $176.33 M(-0.1%) |
| Jun 2024 | - | $176.54 M(+16.1%) |
| Mar 2024 | - | $152.04 M(+29.8%) |
| Dec 2023 | $380.50 M(+29.6%) | $117.18 M(+18.9%) |
| Sep 2023 | - | $98.53 M(+14.0%) |
| Jun 2023 | - | $86.45 M(+10.4%) |
| Mar 2023 | - | $78.34 M(-8.2%) |
| Dec 2022 | $293.57 M(+21.1%) | $85.30 M(+6.1%) |
| Sep 2022 | - | $80.41 M(+14.4%) |
| Jun 2022 | - | $70.27 M(+22.0%) |
| Mar 2022 | - | $57.59 M(-10.9%) |
| Dec 2021 | $242.48 M(+17.3%) | $64.60 M(+2.3%) |
| Sep 2021 | - | $63.16 M(+2.3%) |
| Jun 2021 | - | $61.74 M(+16.5%) |
| Mar 2021 | - | $52.98 M(-11.0%) |
| Dec 2020 | $206.67 M(+117.6%) | $59.55 M(+1.3%) |
| Sep 2020 | - | $58.79 M(+16.8%) |
| Jun 2020 | - | $50.33 M(+32.4%) |
| Mar 2020 | - | $38.01 M(+26.9%) |
| Dec 2019 | $94.97 M(+133.4%) | $29.95 M(+23.8%) |
| Sep 2019 | - | $24.20 M(+6.6%) |
| Jun 2019 | - | $22.70 M(+25.3%) |
| Mar 2019 | - | $18.12 M(+25.4%) |
| Dec 2018 | $40.68 M(+26.9%) | $14.45 M(+27.5%) |
| Sep 2018 | - | $11.33 M(+44.8%) |
| Jun 2018 | - | $7.83 M(+10.7%) |
| Mar 2018 | - | $7.07 M(-20.7%) |
| Dec 2017 | $32.06 M(+27.1%) | $8.91 M(+3.2%) |
| Sep 2017 | - | $8.64 M(+2.3%) |
| Jun 2017 | - | $8.44 M(+38.9%) |
| Mar 2017 | - | $6.08 M(-21.7%) |
| Dec 2016 | $25.22 M(+680.2%) | $7.75 M(-45.0%) |
| Sep 2016 | - | $14.09 M(+434.0%) |
| Jun 2016 | - | $2.64 M(+257.6%) |
| Mar 2016 | - | $738.00 K(-19.6%) |
| Dec 2015 | $3.23 M(-96.1%) | $918.40 K(+4.4%) |
| Sep 2015 | - | $880.00 K(-95.5%) |
| Jun 2015 | - | $19.50 M(-4.1%) |
| Mar 2015 | - | $20.33 M(+2.2%) |
| Dec 2014 | $83.95 M | $19.89 M(+2.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2014 | - | $19.45 M(-10.4%) |
| Jun 2014 | - | $21.70 M(-5.3%) |
| Mar 2014 | - | $22.91 M(-2.3%) |
| Dec 2013 | $87.56 M(+43.3%) | $23.44 M(+7.6%) |
| Sep 2013 | - | $21.79 M(-1.2%) |
| Jun 2013 | - | $22.06 M(+8.9%) |
| Mar 2013 | - | $20.26 M(+14.4%) |
| Dec 2012 | $61.09 M(+15.2%) | $17.70 M(+21.8%) |
| Sep 2012 | - | $14.54 M(+2.9%) |
| Jun 2012 | - | $14.13 M(-3.9%) |
| Mar 2012 | - | $14.71 M(+7.7%) |
| Dec 2011 | $53.02 M(+2.5%) | $13.66 M(-1.6%) |
| Sep 2011 | - | $13.88 M(+3.9%) |
| Jun 2011 | - | $13.36 M(+10.4%) |
| Mar 2011 | - | $12.11 M(-2.4%) |
| Dec 2010 | $51.70 M(-18.8%) | $12.40 M(-8.9%) |
| Sep 2010 | - | $13.61 M(+9.8%) |
| Jun 2010 | - | $12.40 M(-6.6%) |
| Mar 2010 | - | $13.28 M(+13.9%) |
| Dec 2009 | $63.70 M(-33.9%) | $11.66 M(-4.7%) |
| Sep 2009 | - | $12.23 M(-6.6%) |
| Jun 2009 | - | $13.10 M(-50.9%) |
| Mar 2009 | - | $26.71 M(+0.8%) |
| Dec 2008 | $96.32 M(+43.9%) | $26.50 M(-4.4%) |
| Sep 2008 | - | $27.72 M(+24.2%) |
| Jun 2008 | - | $22.32 M(+12.8%) |
| Mar 2008 | - | $19.78 M(+15.8%) |
| Dec 2007 | $66.96 M(+13.2%) | $17.09 M(+11.0%) |
| Sep 2007 | - | $15.39 M(-11.9%) |
| Jun 2007 | - | $17.47 M(+2.7%) |
| Mar 2007 | - | $17.01 M(+30.8%) |
| Dec 2006 | $59.15 M(-16.9%) | $13.01 M(-10.8%) |
| Sep 2006 | - | $14.58 M(-21.2%) |
| Dec 2005 | $71.18 M(+56.4%) | - |
| Mar 2005 | - | $18.50 M(+228.9%) |
| Dec 2004 | $45.52 M(+53.8%) | - |
| Mar 2004 | - | $5.63 M |
| Dec 2003 | $29.60 M(+305.9%) | - |
| Dec 2002 | $7.29 M(+1718.5%) | - |
| Dec 2001 | $401.00 K | - |
FAQ
- What is Madrigal Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual operating expenses year-on-year change?
- What is Madrigal Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly operating expenses year-on-year change?
What is Madrigal Pharmaceuticals annual total operating expenses?
The current annual operating expenses of MDGL is $380.50 M
What is the all time high annual operating expenses for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual total operating expenses is $380.50 M
What is Madrigal Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, MDGL annual total operating expenses has changed by +$86.92 M (+29.61%)
What is Madrigal Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of MDGL is $176.33 M
What is the all time high quarterly operating expenses for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly total operating expenses is $176.54 M
What is Madrigal Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, MDGL quarterly total operating expenses has changed by -$212.00 K (-0.12%)